Frontiers in Precision Medicine 2016 – Cancer, Big Data and the Public

Frontiers in Precision Medicine 2016 – Cancer, Big Data and the Public

The federal Precision Medicine Initiative (PMI) will be the largest study of human genetics and health in history. With a planned cohort of one million Americans, the PMI promises to increase our understanding of the genetic basis of disease and forge the way for new diagnostic and therapeutic innovations. The PMI is linked to an ambitious national initiative, Vice President Joe Biden’s “Cancer Moonshot,” which hopes to accelerate the cure for cancer using big data and precision oncology techniques. Though the technology to undertake these monumental projects exists today, many scientific, legal, economic, and ethical questions remain. This symposium at the University of Utah S.J. Quinney College of Law will host leading national experts in medicine, bioinformatics, law, policy, and ethics who are tackling the major questions raised by precision medicine, the PMI, and the Cancer Moonshot.

View the event program »

Symposium Agenda

December 1, 2016
9:00 a.m. – 5:30 p.m. , S.J. Quinney College of Law, Level 6

9:00-9:10 a.m. – Welcome
9:10-9:30 a.m. – Opening Remarks

Session 1: Tackling Cancer with Precision Data
This session will explore current approaches to clinical precision oncology and the practical aspects of utilizing the large data sets generated in precision oncology for patient care.

This activity has been approved for AMA PRA Category 1 CreditTM.

The Science of Precision Oncology (9:30-10:30 a.m.)
Moderated by Ana Maria Lopez, M.D., M.P.H., University of Utah |presentation|

The Challenges of Big Data (10:40-11:40 a.m.)
Moderated by Kensaku Kawamoto, M.H.S., M.D., Ph.D., University of Utah

Session 2: Precision Prevention (11:50-12:40 p.m.)
Current techniques for cancer prevention based on genetic information will be discussed, specifically in the context of colorectal and lung cancers. Moderated by Cornelia Ulrich, M.S., Ph.D., University of Utah  |presentation|

This activity has been approved for AMA PRA Category 1 CreditTM.

Lunch (12:40-1:20 p.m.)

Keynote Speaker (1:20-2:00 p.m.)
Catalyzing Translational Innovation
Christopher Austin, M.D., National Center for Advancing Translational Sciences

Introduction by Willard Dere, M.D., University of Utah.   |presentation|

This activity has been approved for AMA PRA Category 1 CreditTM.

Session 3: The Public and Precision Medicine
Strategies for recruiting and engaging the public in large cohort research studies while also ensuring that precision medicine approaches are accessible to underserved populations will be presented.

Recruiting Large Research Cohorts (2:10-3:10 p.m.)
Moderated by James Tabery, Ph.D, University of Utah

Engaging the Public in the Program (3:20-4:20 p.m.)
Moderated by Jeffrey Botkin, M.D., M.P.H., University of Utah 

The Ethics of Access and Precision Medicine (4:30-5:30 p.m.)
Moderated by Leslie Francis, J.D., Ph.D., University of Utah  |presentation|

December 2, 2016
9:00 a.m. – 1:00 p.m.,  S.J. Quinney College of Law, Level 6

Session 4: Patenting Precision Medicine (9:00-10:20 a.m.)
How current legal trends limiting the patentability of precision medicine discoveries and techniques may affect their development, availability and quality. Moderated by Jorge Contreras, J.D., University of Utah  |presentation|

Session 5: Providers, Payers, and Laboratory Testing (10:30 a.m.-12:00 p.m.)
Issues of cost-effectiveness, insurance reimbursement, and the practice of precision oncology in laboratory medicine will be presented. Moderated by Allie Grossmann, M.D., Ph.D., University of Utah

This activity has been approved for AMA PRA Category 1 CreditTM.

Concluding Remarks